Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

Manthena V. S. Varma(Pfizer (United States)), R. Scott Obach(Pfizer (United States)), Charles J. Rotter(Pfizer (United States)), Howard Miller(Pfizer (United States)), George Chang(Pfizer (United States)), Stefanus J. Steyn(Pfizer (United States)), Ayman El‐Kattan(Pfizer (United States)), Matthew D. Troutman(Pfizer (United States))
Journal of Medicinal Chemistry
January 13, 2010
Cited by 324

Abstract

Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh). In this study, using a database comprised of Fa, Fg, Fh, and F values for 309 drugs in humans, an analysis of the interrelation of physicochemical properties and the individual parameters was carried out in order to define the physicochemical space for optimum human oral bioavailability. Trend analysis clearly indicated molecular weight (MW), ionization state, lipophilicity, polar descriptors, and free rotatable bonds (RB) influence bioavailability. These trends were due to a combination of effects of the properties on Fa and first-pass elimination (Fg and Fh). Higher MW significantly impacted Fa, while Fg and Fh decreased with increasing lipophilicity. Parabolic trends were observed for bioavailability with polar descriptors. Interestingly, RB has a negative effect on all three parameters, leading to its pronounced effect on bioavailability. In conclusion, physicochemical properties influence bioavailability with typically opposing effects on Fa and first-pass elimination. This analysis may provide a rational judgment on the physicochemical space to optimize oral bioavailability.


Related Papers

No related papers found

Powered by citation graph analysis